Multiple Sclerosis - Next generation therapies signal the start of a new era

With FDA advisory board support for Gilenia (fingolimod), Novartis will move ahead of Merck Serono's oral cladribine in the race to become the first oral multiple sclerosis therapy. Although growth will be stifled by biosimilars, these new product launches will see the multiple sclerosis market grow at a compound annual growth rate (CAGR) of 2.3% over the next 10 years (2009/2019).

The Cardiovascular Market Outlook to 2015:Competitive landscape, global market analysis, key trends and pipeline analysis

This report provides comprehensive coverage of the cardiovascular market, incorporating a disease overview and detailed epidemiological analyses of the major indications. This report makes a wide-ranging assessment of the marketed product portfolio, R&D pipeline, market share data, sales forecast and competitive landscape for the major players.

The Vaccines Market Outlook To 2014: Competitive landscape, pipeline analysis, growth opportunities and market forecasts

This report provides a comprehensive analysis of key vaccine classes and leading companies within the global vaccines market. Leading brands for each major indication within both adult and pediatric population segments are assessed to identify key growth areas and leading products through to 2014. This report reviews the factors and underlying trends that are currently shaping market development.

The Impact of Authorized Generic Pharmaceuticals on the Introduction of Other Generic Pharmaceuticals

This study examines the impact of authorized generic drugs on the introduction of other generic pharmaceuticals, and therefore on the potential benefits of generic drugs for U.S. consumers. The analysis focuses on the incentives and disincentives of generic companies to challenge the patents of brand products, in order to qualify for a special, 180-day period of market exclusivity, when their generic product still faces potential competition in that period from generics authorized by the original developer.

Full 16 pages Report is available for download at Repository.

Type 1 Diabetes - Drug Pipeline Assessment and Market Forecasts to 2017

GlobalData, the industry analysis specialist, has released a new report, "Type 1 Diabetes - Pipeline Assessment and Market Forecasts to 2017". The report is an essential source of information and analysis on the global type 1 diabetes market. The report identifies the key trends shaping and driving the global type 1 diabetes market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the existing market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global type 1 diabetes sector.

Parkinson's Disease - Pipeline Assessment and Market Forecasts to 2016

GlobalData, the industry analysis specialist, has released its latest report, "Parkinson's Disease - Pipeline Assessment and Market Forecasts to 2016 " which provides the key data, information and analysis on the Parkinson's disease (PD) market. The report provides a comprehensive overview of the annualized market data from 2001 to 2009, and forecast seven years to 2016. The research also includes market characterization, opportunities, the unmet needs associated with Parkinson's disease, competitive assessment, the product profiles of the major marketed products and the promising drugs in the pipeline, an overview of the discontinued projects, the implications for future market competition, and the key players in the Parkinson's disease market.

Pulmonary Arterial Hypertension (PAH) - Pipeline Assessment and Market Forecasts to 2016

GlobalData, the industry analysis specialist, has released its latest research, "Pulmonary Arterial Hypertension (PAH) - Pipeline Analysis and Market Forecasts to 2016", which provides key data, information and analysis on the PAH market. The report provides a comprehensive overview of the annualized market data from 2005 to 2009, and forecasts forward seven years to 2016. The research also includes market characterization, opportunities, the unmet needs, competitive assessments, the product profiles of major marketed products and promising drugs in the pipeline, an overview on discontinued projects, implications for future market competition, and the key players of the PAH market.

Dyslipidemia - Pipeline Assessment and Market Forecasts to 2016

GlobalData, the industry analysis specialist's new report, "Dyslipidemia - Pipeline Analysis and Market Forecasts to 2016" is an essential source of information and analysis on the global dyslipidemia market. The report identifies the key trends shaping and driving the global dyslipidemia market. The report also provides insight on the prevalent competitive landscape and the emerging players expected to bring significant shift in the market positioning of the existing market leaders. Most importantly, the report provides valuable insight on the pipeline products within the global dyslipidemia sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in house analysis by GlobalData's team of industry experts.